Therapeutic Strategies in EGFR Mutant Lung Cancer

Therapeutic Strategies in EGFR Mutant Lung Cancer
Author :
Publisher : Frontiers Media SA
Total Pages : 239
Release :
ISBN-10 : 9782832503805
ISBN-13 : 2832503802
Rating : 4/5 (802 Downloads)

Book Synopsis Therapeutic Strategies in EGFR Mutant Lung Cancer by : Yaxiong Zhang

Download or read book Therapeutic Strategies in EGFR Mutant Lung Cancer written by Yaxiong Zhang and published by Frontiers Media SA. This book was released on 2022-11-03 with total page 239 pages. Available in PDF, EPUB and Kindle. Book excerpt:


Therapeutic Strategies in EGFR Mutant Lung Cancer Related Books

Therapeutic Strategies in EGFR Mutant Lung Cancer
Language: en
Pages: 239
Authors: Yaxiong Zhang
Categories: Medical
Type: BOOK - Published: 2022-11-03 - Publisher: Frontiers Media SA

DOWNLOAD EBOOK

Overcoming Resistance to EGFR Inhibitors in EGFR-Mutant NSCLC
Language: en
Pages: 150
Authors: Anthony Faber
Categories: Science
Type: BOOK - Published: 2023-01-30 - Publisher: Academic Press

DOWNLOAD EBOOK

Overcoming Resistance to EGFR Inhibitors in EGFR Mutant NSCLC presents updated information on how EGFR mutant lung cancers evolve to evade EGFR inhibitors, clin
Novel Therapeutic Strategies for Targeting EGFR Mutated Non-small Cell Lung Cancer
Language: en
Pages:
Authors: Neele Drobnitzky
Categories:
Type: BOOK - Published: 2017 - Publisher:

DOWNLOAD EBOOK

New Therapeutic Strategies in Lung Cancers
Language: en
Pages: 255
Authors: Solange Peters
Categories: Medical
Type: BOOK - Published: 2014-10-01 - Publisher: Springer

DOWNLOAD EBOOK

This book provides an up-to-date review of current management techniques for Non-Small Cell Lung Cancer. It addresses all of the latest issues that have been ra
Targeted Therapies in Lung Cancer: Management Strategies for Nurses and Practitioners
Language: en
Pages: 120
Authors: Marianne Davies
Categories: Medical
Type: BOOK - Published: 2019-07-16 - Publisher: Springer

DOWNLOAD EBOOK

This book aims to educate nurses and advanced practice providers (APP’s) about known mutations, availability of targeted therapy and the management of patient